Patent ID: 11926619
Assignee: EISAI R&D MANAGEMENT CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 15:
16. A method of inducing at least one neoantigen, comprising contacting a neoplastic cell with a therapeutically effective amount of a compound and/or pharmaceutically acceptable salt according to any one of claims 1, 5, 6, 8, 9, and 10, or a pharmaceutical composition comprising a compound and/or pharmaceutically acceptable salt according to any one of claims 1, 5, 6, 8, 9, and 10, thereby inducing production of at least one neoantigen; wherein the neoplastic cell is derived from a cancer and the cancer is chosen from myelodysplastic syndrome, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, colon cancer, pancreatic cancer, endometrial cancer, ovarian cancer, breast cancer, uveal melanoma, gastric cancer, cholangiocarcinoma, and lung cancer.